U.S. Supreme Court Justice Stephen Breyer on Oct. 19 turned away a religious challenge to a requirement that healthcare workers in Maine be vaccinated against Covid-19, the latest such bid rejected by the nation’s top judicial body.
Cigna Corp. said on Aug. 26 the company would now sell health insurance plans on online marketplaces created by the Affordable Care Act (ACA), popularly known as Obamacare, in three new U.S. states and 93 new counties.
Bayer, trying to contain billions of dollars in legal costs, filed a petition with the U.S. Supreme Court to reverse an appeals court verdict that upheld damages to a customer blaming his cancer on the German group’s glyphosate-based weedkillers.
A U.S. appeals court on Aug. 10 threw out a price-fixing lawsuit against two Chinese companies that make vitamin C, a case that spotlighted trade tensions between the United States and China.
The U.S. Supreme Court on June 21 declined to hear a bid by health insurance companies to seek a full reimbursement from the federal government under a provision of the Obamacare law aimed at encouraging them to offer medical coverage to uninsured Americans.
The U.S. Supreme Court on June 21 declined to hear AbbVie Inc.’s challenge to a lower court’s decision that the company violated federal antitrust law by pursuing a “sham” patent complaint against rival Perrigo Co. over AbbVie’s blockbuster testosterone replacement drug AndroGel.
The U.S. Supreme Court on June 21 rejected a bid by an Amarin Corp. subsidiary to revive patents on the company’s heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals Plc and Dr. Reddy’s Laboratories Ltd.
The U.S. Supreme Court on June 1 declined to hear Johnson & Johnson’s bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company’s baby powder and other talc products.
The U.S. Supreme Court on May 17 dashed Novartis AG’s hopes of launching a generic version of Amgen Inc.’s multibillion-dollar rheumatoid arthritis medicine Enbrel, declining to hear the company’s challenge to two patents on the drug.
The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for J&J’s failure to warn about risks associated with off-label uses of the antipsychotic drug Risperdal.